Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong performance in Innovative Medicine and MedTech, raising its full-year EPS guidance. UnitedHealth reported a mixed quarter with Medicare costs below plan but commercial insurance costs rising, delaying margin recovery beyond 2027. Investors will watch for changes in J&J’s EPS guidance and UnitedHealth’s medical care ratio to gauge the healthcare sector's direction into 2027.
Johnson & Johnson trades at USD 260.77 on Pluang as of Oct 12, 2026 18:51 WIB, down 0.26% in one day. UnitedHealth Group is priced at USD 380.14, up 0.22% for the day. Both stocks show strong market caps, with JNJ at $630.04B and UNH at $340.46B, reflecting their significant roles in the health sector.
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of ...
Five major U.S. companies—Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Realty Income—are highlighted for their long histories of dividend increases and strong cash flow coverage. These firms offer diverse dividend yields, with some pr...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
